Welcome to our dedicated page for Procept Biorobotics SEC filings (Ticker: PRCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PROCEPT BioRobotics Corporation filings document the public-company disclosures of a Nasdaq-listed surgical robotics business focused on urology. Recent Form 8-K reports furnish quarterly financial results, revenue and operating commentary, investor presentation materials, and updates tied to the company’s AQUABEAM and HYDROS Robotic Systems, Aquablation therapy, and related product and clinical programs.
Proxy and governance filings cover board composition, committee assignments, director independence, executive compensation, equity awards, and severance or change-of-control arrangements. The filings also identify PRCT common stock registered under Section 12(b) and traded on The Nasdaq Global Market.
PROCEPT BioRobotics Corporation reported that its board of directors increased in size from eight to nine members and appointed Daniel Puckett to fill the new seat. He is a Class III director, with an initial term running until the 2027 annual meeting of stockholders.
The board determined that Puckett qualifies as an independent director under SEC and Nasdaq rules and appointed him to the Audit Committee, effective immediately. He is a former Chief Financial Officer of Shockwave Medical, Counsyl and Ariosa Diagnostics, and will receive compensation consistent with other non‑employee directors.
PROCEPT BioRobotics Corporation filed its annual report detailing its surgical robotics business focused on treating benign prostatic hyperplasia (BPH) with its AquaBeam and HYDROS robotic systems. Revenue grew to $308.1 million in 2025 from $224.5 million in 2024, while net loss was $95.6 million, with an accumulated deficit of $641.6 million.
As of December 31, 2025, the company had an installed base of 912 systems globally, including 718 in the United States. Management cites an estimated $30 billion U.S. addressable market for Aquablation therapy and highlights broad reimbursement coverage that it estimates reaches about 95% of U.S. men.
The report emphasizes extensive clinical data supporting Aquablation therapy, growing international presence, ongoing prostate cancer clinical trials, and continued investment in R&D, AI-enabled features, and sales and marketing to expand system placements and procedure volumes.
PROCEPT BioRobotics used its Investor Day to outline rapid growth in Aquablation therapy for benign prostatic hyperplasia and a clearer path to profitability. Total revenue grew from $75M in 2022 to $309M in 2025, while gross margin expanded from 49.4% to 63.7%. U.S. Aquablation procedures rose to 43,300 in 2025 and the global install base reached 718 systems, implying Aquablation penetration of about 10% to 25% of the U.S. surgical market by management estimates.
The company is rolling out the next-generation HYDROS robotic platform, reorganizing its commercial model with dedicated launch teams, and investing heavily in clinical evidence, including the pivotal WATER IV prostate cancer trial. For 2026, it guides revenue of $390–$410M, gross margin of about 65%, and an adjusted EBITDA loss of $30–$17M, with a 2027 target of $25–$30M of adjusted EBITDA and 68–70% gross margin. Management highlights a strong balance sheet, modest capital needs, and expects to remain above $175M in cash while a $52M loan matures in 4Q27.
PROCEPT BioRobotics Corp executive receives stock from performance award
EVP and Chief Legal Officer Nouri Alaleh acquired 4,872 shares of PROCEPT BioRobotics common stock through a grant at a price of $0.00 per share. After this award, Alaleh directly holds 77,345 common shares.
The shares represent common stock underlying a portion of previously granted performance stock units. The company’s Compensation Committee certified on February 19, 2026 that required performance goals were achieved, causing these units to be deemed earned. The earned shares are scheduled to vest on March 5, 2026, with each unit corresponding to one share of common stock.
Waters Kevin reported acquisition or exercise transactions in this Form 4 filing.
PROCEPT BioRobotics Corp EVP and CFO Kevin Waters was granted 3,532 shares of common stock through earned performance stock units. The Form 4 shows these shares at a price of $0.0000 per share, reflecting an award rather than an open-market purchase or sale.
The award represents a portion of previously granted performance stock units that became earned after the compensation committee certified achievement of preset performance goals on February 19, 2026. These earned units are scheduled to vest on March 5, 2026, and each unit corresponds to one share of common stock, bringing Waters’ direct holdings to 111,523 shares after the transaction.
PROCEPT BioRobotics reported strong growth but wider losses for 2025 and reset its 2026 outlook. Q4 2025 revenue was $76.4 million, up 12%, with about 12,200 U.S. procedures and 65 new systems placed. Full-year 2025 revenue reached $308.1 million, a 37% increase, and gross margin improved to 64%, but net loss expanded to $95.6 million.
The U.S. install base grew 42% to 718 systems, while Q4 gross margin slipped to 61% due to lower-than-expected consumable revenue and a one-time field action. For 2026, the company guides revenue to $390–$410 million (27–33% growth), U.S. procedure growth of 39–48%, gross margin around 65%, operating expenses near $350 million, and an adjusted EBITDA loss between $30 million and $17 million. Cash and restricted cash totaled $289.5 million at year-end 2025.
T. Rowe Price Investment Management, Inc. reports beneficial ownership of 3,271,408 shares of PROCEPT BioRobotics Corp common stock, representing 5.9% of the outstanding class as of the reported date. T. Rowe Price has sole voting and dispositive power over all these shares.
The firm states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of PROCEPT. It also expressly denies being the beneficial owner of the securities beyond what is required for this disclosure.
BNP Paribas Asset Management Holding S.A. disclosed a significant ownership position in PROCEPT BioRobotics Corp common stock. As of 12/31/2025, it beneficially owned 3,094,649 shares, representing 5.5% of the outstanding common stock.
The firm reported sole voting power over 2,990,031 shares and sole dispositive power over 3,094,649 shares, with no shared voting or dispositive power. It certified that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of PROCEPT BioRobotics.
FMR LLC filed an amended ownership report showing a significant position in PROCEPT BioRobotics Corp. FMR LLC and Abigail P. Johnson together report beneficial ownership of 4,653,110.77 shares of PROCEPT BioRobotics common stock, representing 8.3% of the outstanding class as of the event date. FMR has sole voting power over 4,646,412 shares and sole dispositive power over 4,653,110.77 shares, while Johnson is reported with sole dispositive power over the same 4,653,110.77 shares. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
PROCEPT BioRobotics (PRCT) reported strong Q3 growth with continued losses. Revenue reached $83.3 million, up 43% year over year, driven by higher system placements, handpieces, and service. Gross margin improved to 65% from 63% as higher volumes spread fixed manufacturing costs. Net loss was $21.4 million, or $0.38 per share, compared to $21.0 million, or $0.40 per share, a year ago.
For the first nine months, revenue was $231.7 million, up 48%, with gross margin at 65%. Cash and cash equivalents were $294.3 million as of September 30, 2025, and stockholders’ equity was $380.3 million. The company had $51.6 million of long‑term debt and amended its loan in August 2025 so the entire principal is due at maturity in 2027, alongside updated cash‑holding requirements tied to balance thresholds. U.S. accounted for 89% of Q3 revenue. The installed base reached 835 AquaBeam and HYDROS robotic systems globally, including 653 in the United States. Shares outstanding were 55,878,589 as of October 29, 2025.